Monthly Prescribing Reference

FreeStyle Libre 2 Cleared for Use in Adults and Pediatric Patients With Diabetes

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
Nasdaq

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
Forbes

2 Million Patients And Beyond: Abbott’s FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
Pharmabiz

US FDA clears Abbott’s FreeStyle Libre 2 iOS application, a seamless digital experience to simplify diabetes management

Abbott, a global healthcare leader, announced that the US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a ...
Pharmabiz

Health Canada approves Abbott’s sensor-based glucose monitoring technology, FreeStyle Libre 2 for adults and children with diabetes

Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval fromHealth Canada for adults and children (4 and older) with diabetes. With new ...